Evidence map›Paper›PMID 42882790›Full record

ArticleCancers2026

Cystic Renal Masses: From Malignancy Probability to Risk-Adapted Management.

Chencan Fang, Chenyi Ge, Lijuan Yin, Xin Lu, Le Qu, Hanzhong Zhang, Yan Zhang, Ying Liu, Yu Fang, Qinqin Kang and 2 more

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chencan FangDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0009-0006-8863-528X
Chenyi GeDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Lijuan YinDepartment of Pathology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0009-0008-0827-9612
Xin LuDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0000-0002-6612-8352
Le QuDepartment of Urology, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing 210002, China.
Hanzhong ZhangDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Yan ZhangDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Ying LiuDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Yu FangDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Qinqin KangDepartment of Radiology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.
Aimin JiangDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0000-0002-9563-983X
Linhui WangDepartment of Urology, Changhai Hospital, Naval Medical University, Shanghai 200433, China.ORCID 0000-0002-6070-1832

Funding

National Key Research and Development Program of China 2022YFB4700904National Natural Science Foundation of China 82372883Shanghai Anti-Cancer Association SACA-CY25C01
6 · The paper itself

Abstract

Cystic renal masses (CRMs) encompass a broad spectrum of conditions ranging from simple renal cysts to cystic renal cell carcinoma. Their detection has increased markedly with the widespread use of abdominal imaging, raising concern about potential overtreatment: many complex CRMs treated surgically are ultimately benign, while some malignant lesions are low grade, localized, and follow a relatively indolent clinical course. Although the Bosniak classification stratifies malignancy probability, translating lesion characteristics into preoperative assessments of biological aggressiveness and patient-specific clinical consequences remains challenging. Drawing on published evidence and common clinical decision-making scenarios, this Perspective outlines the pathologic classification of CRMs, examines the limitations of the Bosniak classification, and discusses the prospects for and current barriers to the use of radiomics and artificial intelligence for benign-versus-malignant classification. With the dual objectives of differentiating benign from malignant lesions and assessing biological aggressiveness, we focus on individualized management strategies that integrate the probability of malignancy, potential clinical harm, and patient-specific factors. These strategies include conservative management, indications for surgery, and selection of surgical approach. The aim is to inform more standardized and precise diagnosis and management of CRMs.

Indexed as

active surveillancebiological aggressivenessBosniak classificationcystic renal massespartial nephrectomyrenal cell carcinoma

Identifiers

PMID42882790
PMCPMC13664434

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.